Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2012 1
2013 3
2014 2
2015 1
2017 1
2018 3
2019 1
2020 3
2021 3
2022 5
2023 4
2024 5
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hoeper compare (22 results)?
Add-on therapy with parenteral prostacyclin analogues in patients with pulmonary arterial hypertension: Insights from the COMPERA registry.
Tello K, Delcroix M, Pausch C, Huscher D, Pittrow D, Ardeschir Ghofrani H, Badagliacca R, Vonk-Noordegraaf A, Kopec G, Halank M, Ewert R, Klose H, Grünig E, Skride A, Ulrich S, Stadler S, Scelsi L, Pfeuffer-Jovic E, Hoeper MM, Olsson KM. Tello K, et al. J Heart Lung Transplant. 2025 Oct 24:S1053-2498(25)02334-4. doi: 10.1016/j.healun.2025.10.019. Online ahead of print. J Heart Lung Transplant. 2025. PMID: 41201625 Free article.
We retrospectively analyzed pretreated patients with idiopathic/heritable/drug-associated PAH (I/H/D-PAH), connective tissue disease-associated PAH (CTD-PAH), or congenital heart disease-associated PAH (CHD-PAH) from the COMPERA registry who received add-on PPA therapy. Am …
We retrospectively analyzed pretreated patients with idiopathic/heritable/drug-associated PAH (I/H/D-PAH), connective tissue disease-associa …
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta-Registry Analysis.
Yogeswaran A, Hassoun PM, Saleh K, Fünderich M, Balasubramanian A, Konswa Z, Kiely DG, Lawrie A, Thenappan T, Eichstaedt CA, Grünig E, Wilkins MR, Howard L, Olschewski H, Kovacs G, Cajigas HR, Frantz R, Sabbour H, Sweatt AJ, Zamanian RT, Arvanitaki A, Giannakoulas G, Elwing J, Jose A, Beckmann S, Olsson KM, Stadler S, Held M, Halank M, Ewert R, Behr J, Milger-Kneidinger K, Pausch C, Pittrow D, Majeed RW, Wilhelm J, Ghofrani HA, Grimminger F, Tello K, Hoeper MM, Seeger W; PVRI-GoDeep-Consortium. Yogeswaran A, et al. Am J Respir Crit Care Med. 2025 Oct;211(10):1855-1866. doi: 10.1164/rccm.202412-2371OC. Am J Respir Crit Care Med. 2025. PMID: 40772955
The survival statistics of patients with PDE5i-treated IIP-PH or IPF-PH were validated in the independent COMPERA registry. Combination therapy with PDE5is and inhaled prostacyclin analogues was superior to monotherapy using PDE5is (hazard ratio, 0.341; 0.205-0.566). ...
The survival statistics of patients with PDE5i-treated IIP-PH or IPF-PH were validated in the independent COMPERA registry. Combinati …
Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model.
Alsumali A, McLaughlin V, Chevure J, Klok R, Zhang W, Martinez EC, Pausch C, De Oliveira Pena J, van de Wetering G, Jootun M, Lautsch D, Hoeper MM. Alsumali A, et al. Adv Ther. 2025 Aug;42(8):3902-3921. doi: 10.1007/s12325-025-03241-4. Epub 2025 Jun 17. Adv Ther. 2025. PMID: 40526255 Free PMC article.
METHODS: State-transition probabilities were obtained from STELLAR, while mortality rates adjusted for risk strata and probabilities of lung/heart-lung transplants were derived from COMPERA PAH registry data and literature. RESULTS: In the base case, a 2-year delay in trea …
METHODS: State-transition probabilities were obtained from STELLAR, while mortality rates adjusted for risk strata and probabilities of lung …
Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis.
Skowasch D, Pausch C, Huscher D, Pittrow D, Wede J, Kreimendahl F, Rosenkranz S, Beckmann S, Held M, Grünig E, Ghofrani HA, Klose H, Skride A, Halank M, Stadler S, Delcroix M, Vonk-Noordegraaf A, Ewert R, Kopec G, Hoeper MM, Olsson KM. Skowasch D, et al. ESC Heart Fail. 2025 Aug;12(4):2726-2735. doi: 10.1002/ehf2.15254. Epub 2025 Mar 4. ESC Heart Fail. 2025. PMID: 40037846 Free PMC article.
METHODS AND RESULTS: Data from adult patients with incident pre-capillary PAH and cardiovascular comorbidities from the COMPERA database (European registry for PH) were analysed. A matched-pair analysis of patients treated with monotherapy versus combination therapy based …
METHODS AND RESULTS: Data from adult patients with incident pre-capillary PAH and cardiovascular comorbidities from the COMPERA datab …
Riociguat in pulmonary arterial hypertension: Application of the 4-strata COMPERA 2.0 risk assessment tool in the PATENT studies.
Hoeper MM, Rosenkranz S, Badesch DB, Humbert M, Langleben D, McConnell JW, Hegab S, Rahner C, Richard JF, Ghofrani HA. Hoeper MM, et al. Respir Med. 2025 Jan;236:107910. doi: 10.1016/j.rmed.2024.107910. Epub 2024 Dec 10. Respir Med. 2025. PMID: 39667586 Free article.
At PATENT-1 Week 12, improvements in COMPERA 2.0 risk strata and median 6-min walk distance were seen with riociguat vs placebo in patients assessed as intermediate-low risk and intermediate-high risk at baseline by COMPERA 2.0. More patients improved their COMPE …
At PATENT-1 Week 12, improvements in COMPERA 2.0 risk strata and median 6-min walk distance were seen with riociguat vs placebo in pa …
Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials.
Rosenkranz S, Ghofrani HA, Hoeper MM, Langleben D, Hegab S, Rahner C, Richard JF, McLaughlin VV. Rosenkranz S, et al. J Heart Lung Transplant. 2025 Feb;44(2):135-146. doi: 10.1016/j.healun.2024.08.018. Epub 2024 Sep 3. J Heart Lung Transplant. 2025. PMID: 39236972 Free article.
Safety, efficacy (6-minute walk distance [6MWD], World Health Organization functional class [WHO-FC], and N-terminal probrain natriuretic peptide [NT-proBNP]), and COMPERA 2.0 risk status were assessed in patients with 0, 1 to 2, or 3 to 4 cardiometabolic comorbidities (ob …
Safety, efficacy (6-minute walk distance [6MWD], World Health Organization functional class [WHO-FC], and N-terminal probrain natriuretic pe …
Application of REVEAL Lite 2 and COMPERA 2.0 risk scores to patients with pulmonary arterial hypertension switching to riociguat in the REPLACE study.
Benza RL, Simonneau G, Ghofrani HA, Corris PA, Langleben D, Rosenkranz S, White RJ, Cheng CC, Campos FTAF, Kim HK, Souza R, Chang M, Rahner C, Meier C, Hoeper MM. Benza RL, et al. J Heart Lung Transplant. 2024 Oct;43(10):1756-1760. doi: 10.1016/j.healun.2024.06.002. Epub 2024 Jun 7. J Heart Lung Transplant. 2024. PMID: 38852934 Free article. Clinical Trial.
This post hoc study applied the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2 and Comparative Prospective Registry of Newly Initiated Therapies for Pulmonary (COMPERA) 2.0 risk-assessment tools to REPLACE to investigate the impact of basel …
This post hoc study applied the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2 and Comparative Prospective …
Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).
McLaughlin V, Alsumali A, Liu R, Klok R, Martinez EC, Nourhussein I, Bernotas D, Chevure J, Pausch C, De Oliveira Pena J, Lautsch D, Hoeper MM. McLaughlin V, et al. Adv Ther. 2024 Jan;41(1):130-151. doi: 10.1007/s12325-023-02684-x. Epub 2023 Oct 18. Adv Ther. 2024. PMID: 37851297 Free PMC article.
Risk stratum-adjusted mortality and lung/heart-lung transplant probabilities were based on COMPERA PAH registry data, and the post-transplant mortality probability was obtained from existing literature. ...
Risk stratum-adjusted mortality and lung/heart-lung transplant probabilities were based on COMPERA PAH registry data, and the post-tr …
Performance of the ESC/ERS 4-strata risk stratification model for pulmonary arterial hypertension with missing variables.
Pausch C, Pittrow D, Hoeper MM, Huscher D. Pausch C, et al. Eur Respir J. 2023 Nov 29;62(5):2301023. doi: 10.1183/13993003.01023-2023. Print 2023 Nov. Eur Respir J. 2023. PMID: 37802633 Free PMC article.
The 4-strata model was developed from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) and cross-validated by the French PH Registry [3, 4]. Both studies included patients when all three variables, i.e. ...
The 4-strata model was developed from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMP …
Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.
Distler O, Ofner C, Huscher D, Jordan S, Ulrich S, Stähler G, Grünig E, Held M, Ghofrani HA, Claussen M, Lange TJ, Klose H, Rosenkranz S, Vonk-Noordegraaf A, Vizza CD, Delcroix M, Opitz C, Pausch C, Scelsi L, Neurohr C, Olsson KM, Coghlan JG, Halank M, Skowasch D, Behr J, Milger K, Remppis BA, Skride A, Jureviciene E, Gumbiene L, Miliauskas S, Löffler-Ragg J, Wilkens H, Pittrow D, Hoeper MM, Ewert R. Distler O, et al. Rheumatology (Oxford). 2024 Apr 2;63(4):1139-1146. doi: 10.1093/rheumatology/kead360. Rheumatology (Oxford). 2024. PMID: 37462520 Free PMC article.
We sought to assess contemporary treatment patterns and survival of patients with various forms of CTD-PAH. METHODS: We analysed data from COMPERA, a European pulmonary hypertension registry, to describe treatment strategies and survival in patients with newly diagnosed PA …
We sought to assess contemporary treatment patterns and survival of patients with various forms of CTD-PAH. METHODS: We analysed data from …
33 results